# Pertuzumab + Trastuzumab

## Phesgo inj 600/600mg/10mL

##### 臨採

| TAH Drug Code      | [IPHES](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPHES)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, Adjuvant, HER2-positive, early stage, at high risk of recurrence, in combination with chemotherapyView additional information. Breast cancer, Neoadjuvant, HER2-positive, locally advanced, inflammatory, or early stage (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen in combination with chemotherapyView additional information. Metastatic breast cancer, HER2-positive, in combination with docetaxel, in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease                                                                                                                                                                                                                                                                                                 |
| Dosing             | Initial dosage, Pertuzumab 1200mg/Trastuzumab 600mg/Hyaluronidase-zzxf 30000units, 15mL, SC over approximately 8 minutes. Maintenance dosage: Pertuzumab 600mg/Trastuzumab 600mg/Hyaluronidase-zzxf 20000units, 10mL, SC over approximately 5 minutes every 3 weeks for 3 to 6 cycles as part of a treatment regimen.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity to pertuzumab, trastuzumab, or hyaluronidase, or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Common Dermatologic: Alopecia (77% ), Injection site disorder (15% ), Radiation injury (19% ), Rash (16% ) Gastrointestinal: Constipation (22% ), Decrease in appetite (17% ), Diarrhea (60% ), Inflammatory disease of mucous membrane (15% ), Nausea (60% ), Stomatitis (25% ), Taste sense altered (17% ), Vomiting (20% ) Hematologic: Anemia, All Grades (36% ), Neutropenia, All Grades (22% ) Musculoskeletal: Arthralgia (24% ) Neurologic: Asthenia (31% ), Headache (17% ), Insomnia (17% ), Sensory neuropathy (16% ) Other: Fatigue (29% ) Serious Cardiovascular: Cardiomyopathy, Heart failure (0.8% ), Left ventricular cardiac dysfunction Hematologic: Febrile neutropenia, Grade 3 or 4 (7% ), Neutropenia, Grade 3 or 4 (14% ) Immunologic: Anaphylaxis, Hypersensitivity reaction (1.2% ) Respiratory: Pulmonary toxicity Other: Infusion reaction (21% ) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/pertuzumab-+-trastuzumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

